Relapse After Venetoclax-Based Therapy: Early vs Late Management
February 10th 2025Panelists review recent ESMO guideline updates for managing early relapse after venetoclax-based time-limited therapy, managing relapse after chemoimmunotherapy or late relapse after venetoclax-based time-limited therapy and defining early versus late relapse.
Read More
Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL Patients
January 15th 2025A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.
Read More
Dr. Niemann on Notable Findings from the GLOW Trial in CLL
January 6th 2023Carsten Niemann, MD, PhD, discusses notable data on patient survival outcomes, as well as the impact of minimal residual disease in the peripheral blood from the phase 3 GLOW trial in patients with chronic lymphocytic leukemia.
Read More